Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai) in January 2012 and started operations on July 2, 2012. Located at Biopolis in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technology.
Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai) in January 2012 and started operations on July 2, 2012. Located at Biopolis in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technology.
Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai) in January 2012 and started operations on July 2, 2012. Located at Biopolis in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technology.